Introduction-There is growing concern about the ability of clinical trials to reliably detect differences between active drugs and placebo. To date, little attention has focused on how interactions between clinical trial investigators and patients may influence study outcomes. We sought to explore what types of interactions with patients investigators considered to be appropriate during placebo-controlled pharmacotherapy studies of major depressive disorder.
entail a significant waste of resources and may pose threats to the public health through their impact on the evidence base of treatment efficacy.
To date, most emphasis on reducing placebo response in trials has focused on improving the accuracy and reliability of the clinician-administered rating scales to assess outcomes. 6 Although failure of raters to comply with standardized quality administration training has been frequently documented, little published data currently exist demonstrating that improving rater quality improves detection of drug-placebo differences. 7 Other potential causes for the increasing placebo effects observed in major depressive disorder (MDD) trials include problems with the validity of rating scales (even when administered reliably), the heterogeneity of depressive syndromes, and recruitment through advertisements that may differentially select for patients particularly responsive to nonspecific clinical interactions. 3 In contrast to the emphasis on rater quality, very little attention has focused on the impact on outcomes resulting from interactions between the investigator and the clinical trial patient. The potential influence of the prescriber's role in pharmacotherapy outcomes was first explored in the 1960s. 8, 9 In particular, the strength of the therapeutic alliance, encapsulating concepts such as empathy, compassion, a helpful attitude, and sympathetic listening, may be a particularly powerful influence on outcomes with drug treatment. 10 One study that did attempt to standardize the role of investigators in a trial was the Treatment of Depression Collaborative Research Program (TDCRP): a National Institute of Mental Health-sponsored study of cognitive therapy, interpersonal therapy, imipramine and placebo treatment of MDD. For this protocol, Fawcett et al 11 composed a clinical management manual for pharmacotherapists to follow. The primary goal of the manual was to standardize imipramine/placebo administration during TDCRP. The manual proposed that visits during the study be limited to 20 to 30 minutes and discouraged sessions shorter than 15 minutes. Among other recommendations, the manual emphasized the need to preserve "empathy, support and those naturally spontaneous and more casual exchanges that permit treatment to be carried out in a warm and truly human way"; (italics in original; p. 313). It specifically prohibited the use of specific psychotherapeutic techniques and "open-ended inquiry into or discussion of interpersonal relationships" (p. 313). The manual also recommended focusing on target symptoms, which aids in the structure of sessions.
Analysis of the TDCRP data found that a greater proportion of the variance in outcomes with imipramine or placebo treatment derived from the effect of the pharmacotherapist rather than from the treatment assignment. 12 Moreover, objective evaluations of therapeutic alliance in the TDCRP found that the strength of the alliance correlated with outcome across all conditions, including pharmacotherapy. This variability in the physician-patient relationship was suggested to be a leading cause for the variability in drug-placebo differences in studies of tricyclic antidepressants. 13, 14 Today, other than the general guidance that investigators should not conduct psychotherapy with participants in trials, there is very little standardization of investigator-patient interactions. Examples of variability that may be of concern include the amount of time the investigator spends with the patient at each visit and the types of verbal and nonverbal interactions that occur in the setting of a clinical trial. Here, we report the results of a questionnaire exploring these issues that was administered to principal investigators (PIs) in a phase 3 placebo-controlled trial for MDD.
MATERIALS AND METHODS
Use of the questionnaire was approved by the Emory Institutional Review Board. The questionnaire was distributed to PIs attending the investigators meeting for a 12-week, phase 3b, randomized, fixed-dose, placebo-controlled clinical trial of a Food and Drug Administration-approved serotonin norepinephrine reuptake inhibitor for the treatment of MDD, conducted in 2009 at sites in the United States and Canada. Primary inclusion criteria for participation in the trial were ages 18 to 75 years, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a current major depressive episode, and a minimum Montgomery-Åsberg Depression Rating Scale score of at least 25 at both screening and baseline visits. Key exclusion criteria were previous failure to respond in the past 3 years to 3 or more antidepressants, 2 adequate courses of psychotherapy, or 1 course of electroconvulsive therapy; current clinically significant suicide risk; substance abuse, post-traumatic stress disorder, or obsessive-compulsive disorder in the past year; current clinically significant medical illness; and lifetime diagnosis of bipolar or psychotic disorder. The results from this clinical trial have not yet been published.
Principal investigators attending the meeting were asked to complete a questionnaire exploring the nature of their interactions with patients participating in clinical trials. No personally identifying information of the respondents was collected. Investigators were informed that the questionnaire was solely for the purpose of research into their attitudes regarding appropriate interactions with patients in clinical trials. The investigators were advised that their participation was completely voluntary; completing the survey reflected consent to participate in the research. The questionnaire asked for the number of studies for which the investigator had performed Clinical Global Impression (CGI) ratings and the usual amount of time they spend with a clinical trial patient at a midstudy visit when evaluating response (including CGI) and tolerability of the study medication. This question was posed as a multiple-option question, with the categories of <10, 10-19, 20-29, and ≥30 minutes.
Investigators were then asked about the acceptability of 26 specific kinds of interactions that could occur between the investigator and the patient participating in a placebo-controlled clinical trial. On the questionnaire, the investigators were instructed to "Consider yourself to be conducting a visit at week 4 of an 8-week placebo-controlled trial of a medication for the treatment of major depressive disorder." The questionnaire asked the investigator to rank the acceptability of the interactions from 1 to 4, where: 1, never acceptable; 2, sometimes acceptable; 3, usually acceptable; and 4, always acceptable. The interactions were grouped into 7 categories: (1) cognitive and (2) behavioral interventions, (3) emotional support, (4) psychological advice giving, (5) general health recommendations, (6) resource referrals, and (7) nonspecific interactions. The interactions listed on the questionnaire were presented in an unstructured, mixed order, and their interaction category was not listed.
Statistical Analysis
Questionnaire data were entered into SPSS version 16.0 (SPSS Inc, Chicago, Ill) for analysis. Means and SDs were computed for continuous data, and categorical data were assessed as frequencies. Principal investigators were grouped into more-and lessexperienced categories based on whether they had conducted CGI ratings in at least 20 or less than 20 previous studies, respectively. Comparisons of means between these groups were conducted with Mann-Whitney U test, due to the highly skewed distribution of the number of previous trials among the investigators.
RESULTS
Nineteen PIs (18 Medical Doctors and 1 Doctor of Osteopathic Medicine) completed the survey. Three PIs did not report the number of studies for which they had previously conducted CGI ratings. Of the remaining 16, the number of studies in which the PIs had previously performed CGI ratings ranged from 0 to 150, with a mean of 55.8. Splitting the data into those PIs who had performed CGI ratings in fewer than 20 trials (n = 6) versus those that had done so in at least 20 trials (n = 10), the respective means were 4.5 and 86.5 (P <0.001).
With respect to the mean time spent with a depressed patient at a midstudy visit, 4 (21%) spent less than 10 minutes; 7 (37%) spent 10 to 19 minutes; 7 (37%) spent 20 to 29 minutes; and 1 (5%) spent at least 30 minutes. These proportions were not significantly different between more-and less-experienced PIs.
The acceptability ratings of the specific interactions are shown in Table 1 . Table 2 provides summed acceptability scores for the items within each category. Less-compared with moreexperienced PIs were significantly more likely to consider as acceptable behavioral (P = 0.042) and cognitive interventions (P = 0.016), psychological advice (P = 0.042), and emotional support (P = 0.016). Nonspecific interactions, health recommendations, and financial resource referrals did not differ by PI experience level. Specific interventions that received consistently low acceptability ratings included the physician relating personal experiences and taking sides on issues relating to employment and family conflicts.
DISCUSSION
These questionnaire data indicate important discrepancies between PIs regarding what types of interactions they consider acceptable during study visits with patients in placebocontrolled trials for major depressive disorder. There is high variability between PIs regarding the amount of time they spend with patients and for specific types of interactions. Forty-two percent of PIs spent 20 minutes or more with trials patients at a midstudy visit.
The finding that less-experienced investigators considered it acceptable to provide behavioral and cognitive interactions is significant in that these differences may impact study outcome. The efficacy of cognitive behavioral therapy (CBT) for MDD and anxiety disorders is well established. 15 Although full recovery from MDD with CBT usually takes at least 12 hourly sessions of therapy, smaller reductions in depressive symptoms from CBT interactions may be sufficient to obscure drug-placebo differences on psychiatric rating scales.
Less-experienced investigators were also more willing to provide psychological advice or emotional support, which strengthen the therapeutic alliance and may thereby increase nonspecific response to treatment. On the other hand, too little supportive work may increase patient dropout and thereby harm the signal-detection level of the study. Among community psychiatrists in Germany, provision of verbal support reduced rates of treatment discontinuation among depressed patients receiving an antidepressant. 16 In clinical trials, patient retention and drug-placebo separation may be enhanced through appropriate instruction to patients regarding their research role in helping to determine whether a drug is effective or not, and by explaining that definitive treatment for their illness is provided upon completion of their participation. 17 That less-experienced PIs endorsed interactions to support the therapeutic alliance is in keeping with the recommendations of the TDCRP manual. 11 Specifically, the manual emphasized warmly greeting the patient and using "special effort…to reinforce the patient's continued hope and optimism regarding improvement" (p. 315). Moreover, "any tendency to administer the pharmacotherapy condition mechanically, to maintain inappropriate distance, to relate in a perfunctory way is antitherapeutic and must be avoided" (p. 319). Limitations on psychotherapy interventions should "not result in the patient's receiving limited emotional support" (p. 320). Among the permitted interventions by psycho-pharmacologists were to (1) develop a positive and meaningful relationship with the physician; (2) provide psychological support via conveying a sense of hope and optimism, especially early in treatment; (3) provide education and information about the illness and medication; (4) provide simple advice, including promoting exercise and socialization; and (5) allow for ventilation and abreaction within the time limits and if it is thought to enhance the therapeutic relationship. Quite at odds with the standard in placebo-controlled trials today, the manual emphasizes the pharmacotherapist should "clearly communicate an expectation that the patient will improve" (p. 314).
The results of the survey also raise issues related to the ethics of the treatment of patients in clinical trials. Specifically, what kinds of education and advice would it be unethical to withhold from patients in trials, in the name of minimizing placebo response? For example, the questionnaire revealed disagreement about whether providing written information to patients about depression was acceptable. Moreover, there were discrepant opinions about providing standard recommendations for sleep hygiene and exercise, a basic educational component of depression treatment. 18 This tension between minimizing placebo response and providing ethical treatment to study patients is worthy of further exploration. 5 Severely curtailing physician-patient interactions in placebo-controlled trials may raise questions of external validity of study's findings. If a study medication only demonstrates efficacy over placebo under conditions that do not reflect routine clinical care, then the actual effectiveness of the drug in clinical practice may be quite weak.
There are several limitations to this initial work exploring investigators' opinions about specific interactions in clinical trials. First, investigators' opinions and attitudes may not correlate with their own personal actions as an investigator. That is, investigators may perform certain interactions more or less frequently than they indicated was "acceptable" on the questionnaire. Second, the survey sample was relatively small, and although the range in trial experience was broad, conducting similar surveys with more investigators (including subinvestigators), and investigators involved in trials for other illnesses, such as psychotic disorders, would be instructive. Finally, for reasons of anonymity, we did not collect any demographic information, but such information may have been helpful in identifying whether age, sex, or other variables could have provided greater explanatory power to the diverse findings.
In summary, the results of this survey indicate significant variability in PIs' attitudes regarding interactions with study patients. The findings from this survey suggest that just as there is need for standardization of raters before the initiation of a clinical trial, there also ought to be some mechanism for generating agreement and standardization between investigators regarding the nature of interactions with study patients. 
